LENZ Therapeutics’ LNZ100, a potential treatment for presbyopia, continues to demonstrate strong efficacy and safety in a Phase 3 trial conducted in China. The drug met its primary and key secondary endpoints, showing statistically significant improvement in near vision for patients with presbyopia. These positive results, alongside the FDA’s recent acceptance of LENZ’s marketing application, bolster confidence in LNZ100’s potential approval and market success.
LENZ Therapeutics’ LNZ100, a potential treatment for presbyopia, continues to demonstrate strong efficacy and safety in a Phase 3 trial conducted in China. The drug met its primary and key secondary endpoints, showing statistically significant improvement in near vision for patients with presbyopia. These positive results, alongside the FDA’s recent acceptance of LENZ’s marketing application, bolster confidence in LNZ100’s potential approval and market success.
Shares of LENZ Therapeutics surged in pre-market trading after positive Phase 3 trial data for its presbyopia treatment. Other notable movers include Healthcare Triangle, Pixie Dust Technologies, and Jet.AI. Meanwhile, SMX, Upexi, and Monopar Therapeutics faced pre-market declines.
